In a dismal year for most marijuana stocks, these three winners have bucked the trend.
News & Analysis: Zynerba Pharmaceuticals
Investors appear to be worried about potential safety issues with its cannabinoid gel.
The stock cooled off along with its cannabis-based peers.
The marijuana craze has hit this clinical-stage pharmaceutical company.
A new patent is generating excitement among investors for this clinical-stage biotech stock.
The biotech received welcome news from the FDA for lead CBD candidate Zygel.
An analyst's optimistic outlook provided a spark for the small biotech.
Shares dropped after disappointing pricing details were released from the company's secondary common stock offering.